GlobeNewswire

InnovMetric releases PolyWorks® 2017, delivering a new control-centric reviewing workflow

Dela

QUEBEC, QC, Canada, May 09, 2017 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, launched PolyWorks 2017, the latest release of the company's universal 3D metrology software platform. PolyWorks 2017 delivers a new control-centric reviewing workflow - a key upgrade for all portable metrology and CNC CMM measurement specialists that need to share large metrology projects, containing hundreds of dimensional and GD&T controls, with colleagues, customers, and suppliers. It also provides a major technology upgrade for large-volume metrology applications, and a unique approach to real-time collision analysis for more efficient CNC CMM project setups.

Control-centric reviewing workflow

"Because they provide invaluable feedback on manufactured parts and on the performance of the manufacturing process, 3D measurements must be efficiently planned and executed by measurement specialists. Then, the results have to be thoroughly reviewed by manufacturing specialists to make informed engineering decisions. With 3D inspection projects designed for planning and executing measurements, time-consuming manipulations are required when sharing measurement results using standard 2D reports. For reviewers, interpreting results found in static tables and snapshots within extensive reports can be challenging, frustrating, and inefficient. Oftentimes, this traditional approach requires back-and-forth communication with measurement specialists to extract additional information from the 3D inspection project," said Marc Soucy, President of InnovMetric. "With the new dimensional-control-centric approach in PolyWorks 2017, the PolyWorks|Inspector(TM) 3D metrology project  is  the report! By enabling measurement specialists to communicate results directly in 3D, considerable productivity gains are guaranteed for our customers. PolyWorks 2017 also empowers reviewers to investigate measurement results contextually in 3D with dynamic navigation tools."

Using the new Control Reviewer in PolyWorks|Inspector(TM) or in the free PolyWorks|Viewer(TM), measurement specialists and manufacturing specialists can now:

  • Access a global list of dimensional controls sorted by characteristic index, making it the ideal tool to prepare first-article inspection reports.
  • Add custom controls to the global list of controls; for example, those measured using manual gauges.
  • Easily split an inspection project into small and logical groups of controls called Control Views.
  • Tie individual controls to specific data alignments and coordinate systems, enabling multicontextual Control Views.
  • Search, sort, and filter controls to highlight critical results.
  • Display control views automatically in 3D with the right point of view.
  • Generate formatted reports automatically.

Major technology upgrade for large-volume metrology applications

InnovMetric is proud to release its most significant technology enhancements for customers who need to assemble and inspect large structures such as those found in the aerospace, shipyard, and energy industries. Users can now:

  • Predefine and configure a list of laser tracker devices, and connect to multiple trackers simultaneously. With PolyWorks 2017, to guide assembly building in real time, switch the active tracker instantaneously and feed measured reflector positions to digital readouts.
  • Align point-to-object using a powerful technique that aligns points to different geometrical characteristics of matched objects (such as center points, axes, or surfaces) and control the alignment direction, weight, and participation to the scaling factor computation for each pair of matched geometries.
  • Probe surface features before their nominal components are defined or the part is aligned to the CAD model.

Real-time collision analysis for more efficient CNC CMM project setups

Measurement specialists who define probing and laser scanning paths on CNC CMMs now have access to a collision analysis engine that detects potential tool collisions with the part or the fixtures, and provides visual feedback on problematic tool paths in the Sequence Editor and the 3D Scene.

Thanks to two major innovations, the PolyWorks collision analysis approach stands out from competing CMM software products:

  • PolyWorks collision analysis is carried out in real time while the measurement sequence is created or edited, such as when new measurement objects are added to a sequence. This allows operators to immediately fix problematic tool paths and avoid accumulating issues.
  • PolyWorks collision analysis is performed both offline and online, and warns users about potential collisions even when they launch a measurement operation outside of the Sequence Editor. Traditionally, this feature is offered solely as an offline functionality in other software.

For more information about PolyWorks 2017, including products, demonstrations, and upcoming PolyWorks Conference events, please visit: www.innovmetric.com.

About InnovMetric Software

Founded in 1994 and headquartered in Quebec, QC, Canada, with subsidiaries worldwide, InnovMetric Software Inc. is the leading provider of universal 3D metrology software solutions. The world's largest industrial manufacturing organizations (Toyota, GM, Volkswagen, Honda, BMW, Daimler, Ford, Rolls-Royce, Pratt & Whitney, Boeing, Embraer, Bombardier, Apple, and many more) trust InnovMetric's PolyWorks® software solutions and associated technical services to maximize the benefits of 3D measurement technologies for their engineering and manufacturing applications.

With its subsidiaries and joint ventures, InnovMetric has more than 250 employees in 14 countries: Canada, United States, Mexico, Brazil, France, Italy, Spain, Netherlands, Sweden, Turkey, India, Thailand, China, and Japan.

Contact: Patrick Castera
Tel: 1-418-688-2061
Email: pcastera@innovmetric.com
Website: www.innovmetric.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InnovMetric Software Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum